Patents Assigned to ICAgen
  • Patent number: 8063080
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: November 22, 2011
    Assignee: Icagen, Inc.
    Inventors: Alan Fulp, Brian Marron, Mark J. Suto, Xiaodong Wang
  • Patent number: 8058274
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, seizure, retinal degeneration, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, neuronal degeneration and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: November 15, 2011
    Assignee: Icagen, Inc.
    Inventors: Thomas Eugene Christos, George S. Amato, Robert N. Atkinson, Maria Graciela Barolli, Lilli Ann Wolf-Gouveia, Mark J. Suto
  • Patent number: 8034954
    Abstract: The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: October 11, 2011
    Assignee: Icagen, Inc.
    Inventors: Gregory J. Pacofsky, Mark J. Suto, Paul Christopher Fritch
  • Patent number: 7893209
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: February 22, 2011
    Assignee: ICAgen, Inc.
    Inventors: Timothy James Jegla, Julie Dickson Witzel
  • Publication number: 20100273256
    Abstract: Methods for isolating K+Hnov genes are provided. The K+Hnov nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.
    Type: Application
    Filed: April 8, 2009
    Publication date: October 28, 2010
    Applicant: ICAGEN, INC.
    Inventors: ANDREW P. MILLER, PING HU, MARK EDWARD CURRAN, MARC RUTTER, JIAN-YING WANG
  • Publication number: 20100273784
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: April 9, 2010
    Publication date: October 28, 2010
    Applicant: Icagen, Inc.
    Inventors: Grant Andrew McNaughton-Smith, George Salvatore Amato, James Barnwell Thomas, JR.
  • Publication number: 20100267782
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Application
    Filed: July 14, 2008
    Publication date: October 21, 2010
    Applicant: Icagen, Inc
    Inventors: Serge Beaudoin, Matthew Scott Johnson, Brain Edward Marron, Mark J. Suto
  • Publication number: 20100267930
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.
    Type: Application
    Filed: March 9, 2010
    Publication date: October 21, 2010
    Applicant: ICAgen, Inc.
    Inventors: Timothy James Jegla, Julie Dickson Witzel
  • Publication number: 20100240663
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, seizure, retinal degeneration, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, neuronal degeneration and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: February 16, 2010
    Publication date: September 23, 2010
    Applicant: Icagen, Inc.
    Inventors: Thomas Eugene Christos, George S. Amato, Robert N. Atkinson, Maria Graciela Barolli, Lilli Ann Wolf-Gouveia, Mark J. Suto
  • Publication number: 20100234343
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Application
    Filed: March 22, 2010
    Publication date: September 16, 2010
    Applicant: Icagen, Inc.
    Inventors: Xiaodong Wang, Alan Fulp, Brian Marron, Serge Beaudoin, Darrick Seconi, Mark Suto
  • Patent number: 7777051
    Abstract: The present invention provides a genus of asymmetric benzimidazole compounds, methods and pharmaceut1cal compositions that are useful as modulators of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: August 17, 2010
    Assignee: Icagen, Inc.
    Inventors: Xiaodong Wang, Alan Bradley Fulp
  • Patent number: 7767450
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: August 3, 2010
    Assignee: ICAgen, Inc.
    Inventors: Timothy James Jegla, Julie Dickson Witzel
  • Publication number: 20100190746
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: November 20, 2009
    Publication date: July 29, 2010
    Applicant: ICAGEN, INC.
    Inventors: Grant A. McNaughton-Smith, James B. Thomas, JR., George S. Amato
  • Patent number: 7741332
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: June 22, 2010
    Assignee: Icagen, Inc.
    Inventors: Grant Andrew McNaughton-Smith, George Salvatore Amato, James Barnwell Thomas, Jr.
  • Patent number: 7709533
    Abstract: The present invention provides a class of chemical compounds useful in the treatment of sickle cell disease, diseases characterized by unwanted or abnormal cell proliferation and for the treatment of ocular disorders such as glaucoma. The active compounds are tri-(aryl or heteroaryl) methane compounds or analogues thereof which further comprise an imine moiety and where the tertiary carbon atom can be replaced with a different atom such as Si, Ge, N or P. The compounds enhance resistance to degradation in a biological medium, inhibit potassium flux in a cell, reduce mammalian cell proliferation, reduce the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: May 4, 2010
    Assignee: Icagen, Inc.
    Inventors: Xiaodong Wang, Alan Bradley Fulp, Darrick Seconi
  • Patent number: 7705158
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: April 27, 2010
    Assignee: Icagen, Inc.
    Inventors: Xiaodong Wang, Alan Fulp, Brian Marron, Serge Beaudoin, Darrick Seconi, Mark Suto
  • Publication number: 20100056637
    Abstract: The present invention provides methods of treating or preventing asthma or an inflammatory disease. In one embodiment, the invention provides compounds and formulations for the treatment of asthma or an inflammatory disease.
    Type: Application
    Filed: September 18, 2009
    Publication date: March 4, 2010
    Applicant: Icagen, Inc.
    Inventors: Neil A. Castle, Gregory C. Rigdon, Douglas S. Krafte, Jeffrey L. Krajewski
  • Publication number: 20100041707
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Application
    Filed: September 16, 2009
    Publication date: February 18, 2010
    Applicant: Icagen, Inc.
    Inventors: Alan Fulp, Brian Marron, Mark J. Suto, Xiaodong Wang
  • Patent number: 7642354
    Abstract: The present invention provides a genus of polycyclic pyrazines of formula (I): wherein A and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- membered heteroaryl, W1 is W2is —CH?, —NH—, —N?, —S—, or —O—; Z1 is Z2 is —CH?, —NH—, —N?, —S—, or —O—; Y is a bond, —CH?N—NH—, —NH—CH2, or —NR5—; s and t are independently integers from 1 to 4; and the substituents R1, R2A, R2B and R3 are as defined in the specification for compounds of formula (I). The polycyclic pyrazine compounds are useful as modulators of potassium ion channels in both therapeutic and diagnostic methods.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: January 5, 2010
    Assignee: Icagen, Inc.
    Inventors: Xiaodong Wang, Kerry Leigh Spear, Alan Bradley Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo
  • Patent number: 7615569
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: November 10, 2009
    Assignee: Icagen, Inc.
    Inventors: Alan Fulp, Brian Marron, Mark J. Suto, Xiaodong Wang